Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Compare

1,768 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARCT Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Arcturus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARCT Stock 12 Month Forecast

Average Price Target

$63.50

▲(416.26%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $63.50 with a high forecast of $140.00 and a low forecast of $35.00. The average price target represents a 416.26% change from the last price of $12.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","141":"$141","41.25":"$41.3","74.5":"$74.5","107.75":"$107.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$63.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,41.25,74.5,107.75,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.99,22.759999999999998,32.53,42.3,52.07,61.839999999999996,71.61,81.38,91.14999999999999,100.91999999999999,110.68999999999998,120.46,130.23,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.99,16.875384615384615,20.76076923076923,24.646153846153844,28.53153846153846,32.41692307692308,36.30230769230769,40.18769230769231,44.073076923076925,47.95846153846154,51.84384615384616,55.729230769230774,59.614615384615384,{"y":63.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.99,14.683076923076923,16.376153846153848,18.06923076923077,19.762307692307694,21.455384615384617,23.14846153846154,24.841538461538462,26.534615384615385,28.22769230769231,29.92076923076923,31.613846153846154,33.30692307692308,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.66,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.58,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.1,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.25,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$140.00

Average Price Target$63.50

Lowest Price Target$35.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

5.69%

Upside

Reiterated

07/30/25

Arcturus Therapeutics' overall stock score reflects significant financial challenges with declining revenues and persistent losses. While there are positive developments in their mRNA therapeutics pipeline and recent corporate events, the financial instability and lack of immediate valuation attractiveness weigh heavily on the score.

Yigal NochomovitzCiti

Citi

$47

Buy

282.11%

Upside

Reiterated

07/14/25

Arcturus Therapeutics: Promising mRNA Developments and High Upside Potential Justify Buy Rating

Yasmeen RahimiPiper Sandler

Piper Sandler

$140

Buy

1038.21%

Upside

Reiterated

07/11/25

Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (NASDAQ: ARCT) and Pharvaris (NASDAQ: PHVS)

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

07/05/25

William Blair Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)

Greg HarrisonScotiabank

Scotiabank

$32→$35

Buy

184.55%

Upside

Reiterated

07/02/25

Scotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)

Pete StavropoulosCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

07/01/25

Cantor Fitzgerald Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

Thomas ShraderBTIG

BTIG

$48

Buy

290.24%

Upside

Reiterated

07/01/25

Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders

Whitney IjemCanaccord Genuity

Canaccord Genuity

$66

Buy

436.59%

Upside

Reiterated

06/30/25

Positive Outlook for Arcturus Therapeutics Amid Promising Developments in ARCT-810 and ARCT-032 Programs

Yanan ZhuWells Fargo

Wells Fargo

$50→$45

Buy

265.85%

Upside

Reiterated

06/30/25

Analysts Are Bullish on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Gilead Sciences (GILD)

Lili (Aurélie) NsongoLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/30/25

Positive Outlook for ARCT-810: Safety and Efficacy Indicators Justify Buy Rating

Ed ArceH.C. Wainwright

H.C. Wainwright

$60

Buy

387.80%

Upside

Reiterated

04/11/25

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements

Seamus FernandezGuggenheim

Guggenheim

$71→$45

Buy

265.85%

Upside

Reiterated

04/10/25

Arcturus Therapeutics price target lowered to $45 from $71 at GuggenheimArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$13

Hold

5.69%

Upside

Reiterated

07/30/25

Yigal NochomovitzCiti

Citi

$47

Buy

282.11%

Upside

Reiterated

07/14/25

Arcturus Therapeutics: Promising mRNA Developments and High Upside Potential Justify Buy Rating

Yasmeen RahimiPiper Sandler

Piper Sandler

$140

Buy

1038.21%

Upside

Reiterated

07/11/25

Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (NASDAQ: ARCT) and Pharvaris (NASDAQ: PHVS)

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

07/05/25

William Blair Reaffirms Their Buy Rating on Arcturus Therapeutics (ARCT)

Greg HarrisonScotiabank

Scotiabank

$32→$35

Buy

184.55%

Upside

Reiterated

07/02/25

Scotiabank Sticks to Its Buy Rating for Arcturus Therapeutics (ARCT)

Pete StavropoulosCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

07/01/25

Cantor Fitzgerald Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)

Thomas ShraderBTIG

BTIG

$48

Buy

290.24%

Upside

Reiterated

07/01/25

Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders

Whitney IjemCanaccord Genuity

Canaccord Genuity

$66

Buy

436.59%

Upside

Reiterated

06/30/25

Positive Outlook for Arcturus Therapeutics Amid Promising Developments in ARCT-810 and ARCT-032 Programs

Yanan ZhuWells Fargo

Wells Fargo

$50→$45

Buy

265.85%

Upside

Reiterated

06/30/25

Analysts Are Bullish on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Gilead Sciences (GILD)

Lili (Aurélie) NsongoLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/30/25

Positive Outlook for ARCT-810: Safety and Efficacy Indicators Justify Buy Rating

Ed ArceH.C. Wainwright

H.C. Wainwright

$60

Buy

387.80%

Upside

Reiterated

04/11/25

Arcturus Therapeutics: Buy Rating Backed by Promising Vaccine Development and Strategic Advancements

Seamus FernandezGuggenheim

Guggenheim

$71→$45

Buy

265.85%

Upside

Reiterated

04/10/25

Arcturus Therapeutics price target lowered to $45 from $71 at GuggenheimArcturus Therapeutics price target lowered to $45 from $71 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcturus Therapeutics

1 Month

xxx

Success Rate

8/11 ratings generated profit

Average Return

-3.62%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of -3.62% per trade.

3 Months

xxx

Success Rate

4/12 ratings generated profit

Average Return

-6.15%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -6.15% per trade.

1 Year

Yasmeen RahimiPiper Sandler

Success Rate

3/16 ratings generated profit

Average Return

-25.69%

reiterated a buy rating 25 days ago

Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -25.69% per trade.

2 Years

xxx

Success Rate

2/11 ratings generated profit

Average Return

-22.74%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 18.18% of your transactions generating a profit, with an average return of -22.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARCT Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARCT has received 24 Buy Ratings, 16 Hold Ratings, and 0 Sell Ratings. ARCT average Analyst price target in the past 3 months is 63.50.

Each month's total comprises the sum of three months' worth of ratings.

ARCT Financial Forecast

ARCT Earnings Forecast

Next quarter’s earnings estimate for ARCT is -$0.90 with a range of -$1.76 to -$0.34. The previous quarter’s EPS was -$0.52. ARCT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.18% of the time in the same period. In the last calendar year ARCT has Preformed in-line its overall industry.

ARCT Sales Forecast

Next quarter’s sales forecast for ARCT is $18.71M with a range of $0.00 to $29.70M. The previous quarter’s sales results were $25.48M. ARCT beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year ARCT has Preformed in-line its overall industry.

ARCT Stock Forecast FAQ

What is ARCT’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is 63.50.

What is ARCT’s upside potential, based on the analysts’ average price target?

Arcturus Therapeutics has 416.26% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARCT a Buy, Sell or Hold?

Arcturus Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Arcturus Therapeutics’s price target?

The average price target for Arcturus Therapeutics is 63.50. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $35.00. The average price target represents 416.26% Increase from the current price of $12.3.

What do analysts say about Arcturus Therapeutics?

Arcturus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ARCT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

ARCT Analyst Ratings

ARCT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcturus Therapeutics

ARCT Analyst Recommendation Trends

ARCT Financial Forecast

ARCT Earnings Forecast

ARCT Sales Forecast

ARCT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts